{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:10:40Z","timestamp":1753881040994,"version":"3.41.2"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,8,20]]},"abstract":"<jats:p>\n            Effective bacterial infection eradication requires not only potent antibacterial agents but also proper dosing strategies. Current practices generally utilize point estimates of the effects of therapeutic agents, even though the actual kinetics of exposure are much more complex and relevant. Here, we use a full time course of the observed\n            <jats:italic>in vitro<\/jats:italic>\n            effects to develop a semimechanistic pharmacokinetic-pharmacodynamic model for eravacycline against multiple Gram-negative bacterial pathogens.\n          <\/jats:p>","DOI":"10.1128\/aac.01308-20","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T14:28:30Z","timestamp":1593527310000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Semimechanistic Modeling of Eravacycline Pharmacodynamics Using\n            <i>In Vitro<\/i>\n            Time-Kill Data with MIC Incorporated in an Adaptive Resistance Function"],"prefix":"10.1128","volume":"64","author":[{"given":"Ken","family":"Nguyen","sequence":"first","affiliation":[{"name":"Experimental Therapeutic Branch, Department of Clinical Pharmacology, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Bensman","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui (Tracey)","family":"Wei","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason N.","family":"Moore","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.01.003"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1139\/cjm-2013-0089"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.08.033"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425250902913808"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmm.IJMM_17_278"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.06.015"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.02.001"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(02)00029-8"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro862"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3670-3676.2004"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw480"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00182-11"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005769"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00604-06"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9069-x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2016.1123250"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01468-07"},{"key":"e_1_3_2_19_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standard Institute","year":"2018","unstructured":"Clinical and Laboratory Standard Institute. 2018. Performance standards for antimicrobial susceptibility testing. CLSI document M100. CLSI, Wayne, PA."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-1856-x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01781-17"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.VMBF-0016-2015"},{"key":"e_1_3_2_23_2","volume-title":"Methods for determining bactericidal activity of antimicrobial agents: approved guideline M26-A","author":"Clinical and Laboratory Standards Institute","year":"1998","unstructured":"Clinical and Laboratory Standards Institute. 1998. Methods for determining bactericidal activity of antimicrobial agents: approved guideline M26-A. CLSI, Wayne, PA."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-7-11"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1064"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011555016423"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01308-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01308-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:58:35Z","timestamp":1645480715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01308-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8,20]]}},"alternative-id":["10.1128\/AAC.01308-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.01308-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"2020-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01308-20"}}